Mri-safe implantable medical device
Abstract
A medical lead is provided for use in a pulse stimulation system of the type which includes a pulse generator for producing electrical stimulation therapy. The lead comprises an elongate insulating body and at least one electrical conductor within the insulating body. The conductor has a proximal end configured to be electrically coupled to the pulse generator and has a DC resistance in the range of 375-2000 ohms. At least one distal electrode is coupled to the conductor.

Term
Term ended
Expired 30 November 2024, 1.8 years ago.
- Priority
- Filed
- Granted
- Expired
- Today
9 claims: 9 independent, 0 dependent
- 1An implantable medical lead for use in a neurostimulation system of the type which includes a stimulator (102) for generating electrical stimulation therapy, the lead comprising:an elongate insulating body (120);at least one electrical conductor (106) within said insulating body (120), and configured to be electrically coupled to the neurostimulator (102);andat least one distal electrode (114) coupled to said conductor (106),characterized in that said conductor (106) having an absolute impedance in the range of 15-885 ohms/centimeter at approximately 64 MHz. Dérivation médicale implantable ou conducteur médical implantable à utiliser dans un système de neurostimulation du type qui inclut un stimulateur (102) pour générer une thérapie par stimulation électrique, la dérivation comportant : un corps isolant allongé (120) ;au moins un conducteur électrique (106) contenu dans le dit corps isolant (120), et configuré pour être électriquement couplé au neurostimulateur (102) ;etau moins une électrode distale (114) couplée audit conducteur (106),caractérisé en ce que ledit conducteur (106) a une impédance absolue comprise dans la plage de 15 à 885 ohms/centimètre à approximativement 64 MHz. Implantierbare Medizinische Leitung zur Verwendung in einem Neurostimulationssystem in der Bauart, welche einen Anreger (102) zum Generieren einer elektrischen Reiztherapie enthält, wobei die Leitung aufweist: einen länglichen Isolierkörper (120);zumindest einen elektrischen Leiter (106) innerhalb des Isolierkörpers (120), der ausgebildet ist, um mit dem Neurostimulator (102) verbunden zu sein;undzumindest eine distale Elektrode (114), die mit dem Leiter (106) verbunden ist,dadurch gekennzeichnet, dass der Leiter (106) eine absolute Impedanz in dem Bereich von 15-885 Ohm/Zentimeter bei ungefähr 64 MHz aufweist.
- 2A medical lead according to claim 1, wherein said conductor has a DC resistance which is in the range of 550-650 ohms. Dérivation médicale selon la revendication 1, dans laquelle ledit conducteur a une résistance DC qui est comprise dans la plage de 550 à 650 ohms. Medizinische Leitung nach Anspruch 1, wobei der Leiter einen Gleichstromwiderstand aufweist, der in dem Bereich von 550-650 Ohm liegt.
- 3A medical lead according to claim 1 wherein the lead has a resistance in the range of 5-20 ohms/centimeter. Dérivation médicale selon la revendication 1, dans laquelle la dérivation a une résistance comprise dans la plage de 5 à 20 ohms/centimètre. Medizinische Leitung nach Anspruch 1, wobei die Leitung einen Widerstand in dem Bereich von 5-20 Ohm/Zentimeter aufweist.
- 4A medical lead according to claim 1 wherein the lead has an inductance greater than 40nH /centimeter. Dérivation médicale selon la revendication 1, dans laquelle la dérivation a une inductance supérieure à 40nH/centimètre. Medizinische Leitung nach Anspruch 1, wobei die Leitung eine Induktivität größer als 40nH/Zentimeter auweist.
- 5A medical lead according to claim 1 wherein said electrical conductor (106) is helically wound. Dérivation médicale selon la revendication 1, dans laquelle ledit conducteur électrique (106) est enroulé de manière hélicoïdale. Medizinische Leitung nach Anspruch 1, wobei der elektrische Leiter (106) schraubenförmig gewickelt ist.
- 6A medical lead according to claim 1 wherein said conductor (106) has an inductance in the range of 40nH/centimeter to 2.2µH/centimeter. Dérivation médicale selon la revendication 1, dans laquelle ledit conducteur (106) a une inductance comprise dans la plage de 40nH/centimètre à 2,2µH/centimètre. Medizinische Leitung nach Anspruch 1, wobei der Leiter (106) eine Induktivität in dem Bereich von 40nH/Zentimeter bis 2,2µH/Zentimeter aufweist.
- 7A medical lead according to claim 1 wherein said electrical conductor (106) is substantially straight. Dérivation médicale selon la revendication 1, dans laquelle ledit conducteur électrique (106) est en grande partie droit. Medizinische Leitung nach Anspruch 1, wobei der elektrische Leiter (106) im Wesentlichen geradlinig ist.
- 8A medical lead according to claim 2 wherein said DC resistance is substantially uniformly distributed along the length of said conductor (106). Dérivation médicale selon revendication 2, dans laquelle ladite résistance DC est en grande partie répartie uniformément le long de la longueur dudit conducteur (106). Medizinische Leitung nach Anspruch 2, wobei der Gleichstromwiderstand im Wesentlichen gleichmäßig entlang der Länge des Leiters (106) verteilt ist.
- 9A medical lead according to claim 1 wherein said absolute impedance is approximately 20 ohms/centimeter. Dérivation médicale selon la revendication 1, dans laquelle ladite impédance absolue est approximativement de 20 ohms/centimètre. Medizinische Leitung nach Anspruch 1, wobei die absolute Impedanz ungefähr 20 Ohm/Zentimeter ist.
Independent claims9
48 paragraphs in 8 sections, as filed
FIELD OF THE INVENTION
The present invention generally relates to implantable medical devices, and more particularly to an implantable medical device such as a neurostimulation system which, when used in an MRI (Magnetic Resonance Imaging) environment does not result in the generation of unwanted heat.
BACKGROUND OF THE INVENTION
Implantable medical devices are commonly used today to treat patients suffering from various ailments. Such implantable devices may be utilized to treat conditions such as pain, incontinence, sleep disorders, and movement disorders such as Parkinson's disease and epilepsy. Such therapies also appear promising in the treatment of a variety of psychological, emotional, and other physiological conditions.
One known type of implantable medical device, a neurostimulator, delivers mild electrical impulses to neural tissue using an electrical lead. For example, to treat pain, electrical impulses may be directed to specific sites. Such neurostimulation may result in effective pain relief and a reduction in the use of pain medications and/or repeat surgeries.
Typically, such devices are totally implantable and may be controlled by a physician or a patient through the use of an external programmer. Current systems generally include a non-rechargeable primary cell neurostimulator, a lead extension, and a stimulation lead, and the two main classes of systems may be referred to as: (1) Spinal Cord Stimulation (SCS) and (2) Deep Brain Stimulation (DBS).
An SCS stimulator may be implanted in the abdomen, upper buttock, or pectoral region of a patient and may include at least one extension running from the neurostimulator to the lead or leads which are placed somewhere along the spinal cord. Each of the leads (to be discussed in detail hereinbelow) currently contain from one to eight electrodes. Each extension (likewise to be discussed in detail below) is plugged into or connected to the neurostimulator at a proximal end thereof and is coupled to and interfaces with the lead or leads at a distal end of the extension or extensions.
The implanted neurostimulation system is configured to send mild electrical pulses to the spinal cord. These electrical pulses are delivered through the lead or leads to regions near the spinal cord or the nerve selected for stimulation. Each lead includes a small insulated wire coupled to an electrode at the distal end thereof through which the electrical stimulation is delivered. Typically, the lead also comprises a corresponding number of internal wires to provide separate electrical connection to each electrode such that each electrode may be selectively used to provide stimulation. Connection of the lead to an extension may be accomplished by means of a connector block including, for example, a series or combination of set-screws, ball-seals, etc.. The leads are inserted into metal set screw blocks, and metal set screws are manipulated to press the contacts against the blocks to clamp them in place and provide an electrical connection between the lead wires and the blocks. Such an arrangement is shown in <patcit id="pcit0001" dnum="US5458629A"><text>U.S. Patent No. 5,458,629 issued October 17, 1995</text></patcit> and entitled "Implantable Lead Ring Electrode and Method of Making".
A DBS system comprises similar components (i.e. a neurostimulator, at least one extension, and at least one stimulation lead) and may be utilized to provide a variety of different types of electrical stimulation to reduce the occurrence or effects of Parkinson's disease, epileptic seizures, or other undesirable neurological events. In this case, the neurostimulator may be implanted into the pectoral region of the patient. The extension or extensions may extend up through the patient's neck, and the leads/electrodes are implanted in the brain. The leads may interface with the extension just above the ear on both sides of the patient. The distal end of the lead may contain from four to eight electrodes and, as was the case previously, the proximal end of the lead may be connected to the distal end of the extension and held in place by set screws. The proximal portion of the extension plugs into the connector block of the neurostimulator.
Magnetic resonance imaging (MRI) is a relatively new and efficient technique that may be used in the diagnosis of many neurological disorders. It is an anatomical imaging tool which utilizes non-ionizing radiation (i.e. no x-rays or gamma rays) and provides a non-invasive method for the examination of internal structure and function. For example, MRI permits the study of the overall function of the heart in three dimensions significantly better than any other imaging method. Furthermore, imaging with tagging permits the non-invasive study of regional ventricular function.
MRI scanning is widely used in the diagnosis of diseases and injuries to the head. In fact, the MRI is now considered by many to be the preferred standard of care, and failure to prescribe MRI scanning can be considered questionable. For example, approximately sixteen million MRIs were performed in 1996 followed by approximately twenty million in the year 2000. It is projected that forty million MRIs will be performed in 2004.
In an MRI scanner, a magnet creates a strong magnetic field which aligns the protons of hydrogen atoms in the body and then exposes them to radio frequency (RF) energy from a transmitter portion of the scanner. This spins the various protons, and they produce a faint signal that is detected by a receiver portion of the scanner. A computer renders these signals into an image. During this process, three electromagnetic fields are produced; i.e. (1) a static magnetic field, (2) a gradient magnetic field, and (3) a radio frequency (RF) magnetic field. The main or static magnetic field may typically vary between 0.2 and 3.0 Tesla. A nominal value of 1.5 Tesla is approximately equal to 15,000 Gauss which is 30,000 times greater than the Earth's magnetic field of approximately 0.5 Gauss. The time varying or gradient magnetic field may have a maximum strength of approximately 40 milli-Tesla/meter at a frequency of 0-5 KHz. The RF may, for example, produce thousands of watts at frequencies of between 8-128 MHz. For example, up to 20,000 watts may be produced at 64 MHz and a static magnetic field of 1.5 Tesla; that is, 20 times more power than a typical toaster. Thus, questions have arisen regarding the potential risk associated with undesirable interaction between the MRI environment and the above-described neurostimulation systems; e.g. forces and torque on the implantable device within the MRI scanner caused by the static magnetic field, RF-induced heating, induced currents due to gradient magnetic fields, device damage, and image distortion. Of these interactions, the problems associated with induced RF currents in the leads are most deserving of attention since it has been found that the temperature in the leads can rise by as much as 25° Centigrade or higher in an MRI environment.
Accordingly, it would be desirable to provide an implantable medical device that may be safely operated in an MRI environment. It would be further desirable to provide an implantable medical device such as a SCS or DBS neurostimulation system that may be operated in an MRI environment without the generation of significant heat in the leads due to induced RF currents. Furthermore, other desirable features and characteristics of the present invention will become apparent from the subsequent detailed description of the invention and the appended claims, taken in conjunction with the accompanying drawings and this background of the invention.
Document <patcit id="pcit0002" dnum="US5335657A"><text>US-A-5 335 657</text></patcit> discloses a device as described in the preamble of claim 1.
BRIEF SUMMARY OF THE INVENTION
According to the invention, there is provided an implantable medical lead for use in a neurostimulation system of the type which includes a stimulator for generating electrical stimulation therapy, the lead comprising: an elongate insulating body; at least one electrical conductor within said insulating body, said conductor having an absolute impedance in the range of 15-885 ohms/centimeter at approximately 64 MHz and configured to be electrically coupled to the neurostimulator; and at least one distal electrode coupled to said conductor.
BRIEF DESCRIPTION OF THE DRAWINGS
The present invention will hereinafter be described in conjunction with the accompanying drawing, wherein like reference numerals denote like elements; and <ul id="ul0001" list-style="none" compact="compact"><li>[0015] <figref idref="f0001">FIG. 1</figref> illustrates a typical spinal cord stimulation system implanted in a patient;</li><li><figref idref="f0002">FIG. 2</figref> illustrates a typical deep brain stimulation system implanted in a patient;</li><li><figref idref="f0003">FIG. 3</figref> is an isometric view of the distal end of the lead shown in <figref idref="f0002">FIG. 2</figref>;</li><li><figref idref="f0003">FIG. 4</figref> is an isometric view of the distal end of the extension shown in <figref idref="f0002">FIG. 2</figref>;</li><li><figref idref="f0003">FIG. 5</figref> is an isometric view of an example of a connecter screw black suitable for connecting the lead of <figref idref="f0003">FIG. 3</figref> to the extension shown in <figref idref="f0003">FIG. 4</figref>;</li><li><figref idref="f0004">FIG. 6</figref> is a top view of the lead shown in <figref idref="f0002">FIG. 2</figref>;</li><li><figref idref="f0004">FIGs. 7 and 8</figref> are cross-sectional views taken along lines 7-7 and 8-8, respectively, in <figref idref="f0004">FIG. 6</figref>;</li><li><figref idref="f0004">FIG. 9</figref> is a top view of an alternate lead configuration;</li><li><figref idref="f0005">FIGs. 10 and 11</figref> are longitudinal and radial cross-sectional views, respectively, of a helically wound lead of the type shown in <figref idref="f0004">FIG. 6</figref>;</li><li><figref idref="f0005">FIGs. 12 and 13</figref> are longitudinal and radial cross-sectional views, respectively, of a cabled lead;</li><li><figref idref="f0006">FIG. 14</figref> is an exploded view of a neurostimulation system;</li><li><figref idref="f0006">FIG. 15</figref> is a cross-sectional view of the extension shown in <figref idref="f0006">FIG. 14</figref> taken along line 15-15;</li><li><figref idref="f0007">FIG. 16</figref> illustrates a discrete inductor in the distal electrode of a lead;</li><li><figref idref="f0007">FIG. 17</figref> is a cross-sectional view of a prismatic discrete inductor in a distal electrode; and</li><li><figref idref="f0007">FIG. 18</figref> is a cross-sectional view of a quadripolar coaxially-wound lead.</li></ul>
DETAILED DESCRIPTION OF THE INVENTION
The following detailed description of the invention is merely exemplary in nature and is not intended to limit the invention or the application and uses of the invention. Furthermore, there is no intention to be bound by any theory presented in the preceding background of the invention or the following detailed description of the invention.
<figref idref="f0001">FIG. 1</figref> illustrates a typical SCS system implanted in a patient. As can be seen, the system comprises a pulse generator such as a SCS neurostimulator 20, a lead extension 22 having a proximal end coupled to neurostimulator 20 as will be more fully described below, and a lead 24 having a proximal end coupled to the distal end of extension 22 and having a distal end coupled to one or more electrodes 26. Neurostimulator 20 is typically placed in the abdomen of a patient 28, and lead 24 is placed somewhere along spinal cord 30. As stated previously, neurostimulator 20 may have one or two leads each having four to eight electrodes. Such a system may also include a physician programmer and a patient programmer (not shown). Neurostimulator 20 may be considered to be an implantable pulse generator of the type available from Medtronic, Inc. and capable of generating multiple pulses occurring either simultaneously or one pulse shifting in time with respect to the other, and having independently varying amplitudes and pulse widths. Neurostimulator 20 contains a power source and the electronics for sending precise, electrical pulses to the spinal cord to provide the desired treatment therapy. While neurostimulator 20 typically provides electrical stimulation by way of pulses, other forms of stimulation may be used such as continuous electrical stimulation.
Lead 24 is a small medical wire having special insulation thereon and includes one or more insulated electrical conductors each coupled at their proximal end to a connector and to contacts 26 at its distal end. Some leads are designed to be inserted into a patient percutaneously (e.g. the Model 3487A Pisces - Quad® lead available from Medtronic, Inc.), and some are designed to be surgically implanted (e.g. Model 3998 Specify® lead, also available from Medtronic, Inc.). Lead 24 may contain a paddle at its distant end for housing electrodes 26; e.g. a Medtronic paddle having model number 3587A. Alternatively, electrodes 26 may comprise one or more ring contacts at the distal end of lead 24 as will be more fully described below.
While lead 24 is shown as being implanted in position to stimulate a specific site in spinal cord 30, it could also be positioned along the peripheral nerve or adjacent neural tissue ganglia or may be positioned to stimulate muscle tissue. Furthermore, electrodes/contacts 26 may be epidural, intrathecal or placed into spinal cord 30 itself Effective spinal cord stimulation may be achieved by any of these lead placements. While the lead connector at proximal end of lead 24 may be coupled directly to neurostimulator 20, the lead connector is typically coupled to lead extension 22 as is shown in <figref idref="f0001">FIG. 1</figref>. An example of a lead extension is Model 7495 available from Medtronic, Inc.
A physician's programmer (not shown) utilizes telemetry to communicate with the implanted neurostimulator 20 to enable the physician to program and manage a patient's therapy and troubleshoot the system. A typical physician's programmer is available from Medtronic, Inc. and bears Model No. 7432. Similarly, a patient's programmer (also not shown) also uses telemetry to communicate with neurostimulator 20 so as to enable the patient to manage some aspects of their own therapy as defined by the physician. An example of a patient programmer is Model 7434 Itrel® 3 EZ Patient Programmer available from Medtronic, Inc.
Implantation of a neurostimulator typically begins with the implantation of at least one stimulation lead while the patient is under a local anesthetic. While there are many spinal cord lead designs utilized with a number of different implantation techniques, the largest distinction between leads revolves around how they are implanted. For example, surgical leads have been shown to be highly effective, but require a laminectomy for implantation. Percutaneous leads can be introduced through a needle, a much easier procedure. To simplify the following explanation, discussion will focus on percutaneous lead designs, although it will be understood by those skilled in the art that the inventive aspects are equally applicable to surgical leads. After the lead is implanted and positioned, the lead's distal end is typically anchored to minimize movement of the lead after implantation. The lead's proximal end is typically configured to connect to a lead extension 22. The proximal end of the lead extension is then connected to the neurostimulator 20.
<figref idref="f0002">FIG. 2</figref> illustrates a DBS system implanted in a patient 40 and comprises substantially the same components as does an SCS; that is, at least one neurostimulator, at least one extension, and at least one stimulation lead containing one or more electrodes. As can be seen, each neurostimulator 42 is implanted in the pectoral region of patient 40. Extensions 44 are deployed up through the patient's neck, and leads 46 are implanted in the patient's brain as is shown at 48. As can be seen, each of leads 46 is connected to its respective extension 44 just above the ear of both sides of patient 40.
<figref idref="f0003">FIG. 3</figref> is an isometric view of the distal end of lead 46. In this case, four ring electrodes 48 are positioned on the distal end of lead 46 and coupled to internal conductors or filers (not shown) contained within lead 46. Again, while four ring electrodes are shown in <figref idref="f0003">FIG. 3</figref>, it is to be understood that the number of electrodes can vary to suit a particular application.
<figref idref="f0003">FIG.4</figref> is an isometric view of the distal end of extension 44, which includes a connector portion 45 having four internal contacts 47. The proximal end of the DBS lead, shown in <figref idref="f0003">FIG. 3</figref>, plugs into distal connector 45 of extension 44 and is held in place by means of, for example, a plurality (e.g. four) of set screws 50. For example, referring to <figref idref="f0003">FIG. 5</figref>, lead 46 terminates in a series of proximal electrical ring contacts 48 (only one of which is shown in <figref idref="f0003">FIG. 5</figref>). Lead 46 may be inserted through an axially aligned series of openings 52 (again only one shown) in screw block 54. With lead 46 so inserted, a series of set screws 50 (only one shown) are screwed into blocks 54 to drive contacts 48 against blocks 54 and secure and electrically couple lead 46. It should be appreciated, however, that other suitable methods for securing lead 46 to extension 44 may be employed. The proximal portion of extension 44 is secured to neurostimulator 42 as is shown in <figref idref="f0001">FIGS. 1</figref> and <figref idref="f0002">2</figref>.
<figref idref="f0004">FIG. 6</figref> is a top view of lead 46 shown in <figref idref="f0002">FIG. 2</figref>. <figref idref="f0004">FIGS. 7 and 8</figref> are cross-sectional views taken along lines 7-7 and 8-8 in <figref idref="f0004">FIG. 6</figref>. Distal end 60 of lead 46 includes at least one electrode 62 (four are shown). As stated previously, up to eight electrodes may be utilized. Each of electrodes 62 is preferably constructed as is shown in <figref idref="f0004">FIG. 8</figref>. That is, electrode 62 may comprise a conductive ring 71 on the outer surface of the elongate tubing making up distal shaft 60. Each electrode 62 is electrically coupled to a longitudinal wire 66 (shown in <figref idref="f0004">FIGS. 7 and 8</figref>) which extends to a contact 64 at the proximal end of lead 46. Longitudinal wires 66 may be of a variety of configurations; e.g. discreet wires, printed circuit conductors, etc. From the arrangement shown in <figref idref="f0004">FIG. 6</figref>, it should be clear that four conductors or filers run through the body of lead 46 to electrically connect the proximal electrodes 64 to the distal electrodes 66. As will be further discussed below, the longitudinal conductors 66 may be spirally configured along the axis of lead 46 until they reach the connector contacts.
The shaft of lead 46 preferably has a lumen 68 extending therethrough for receiving a stylet that adds a measure of rigidity during installation of the lead. The shaft preferably comprises a comparatively stiffer inner tubing member 70 (e.g. a polyamine, polyamide, high density polyethylene, polypropylene, polycarbonate or the like). Polyamide polymers are preferred. The shaft preferably includes a comparatively softer outer tubing member 72; e.g. silicon or other suitable elastomeric polymer. The conducive rings 71 are preferably of a biocompatible metal such as one selected from the noble group of metals, preferably palladium, platinum or gold and their alloys.
<figref idref="f0004">FIG. 9</figref> illustrates an alternative lead 74 wherein distal end 76 is broader or paddle-shaped to support a plurality of distal electrodes 78. A lead of this type is shown in <figref idref="f0001">FIG. 1</figref>. As was the case with the lead shown in <figref idref="f0004">FIGS. 6, 7 and 8</figref>, distal electrodes 78 are coupled to contacts 64 each respectively by means of an internal conductor or filer. A more detailed description of the leads shown in the <figref idref="f0004">FIGS. 6 and 9</figref> may be found in <patcit id="pcit0003" dnum="US6529774B"><text>U.S. Patent No. 6,529,774 issued March 4, 2003</text></patcit> and entitled "Extradural Leads, Neurostimulator Assemblies, and Processes of Using Them for Somatosensory and Brain Stimulation".
Leads of the type described above may be of the wound helix filer type or of the cabled filer type. <figref idref="f0005">FIGs. 10 and 11</figref> are longitudinal and radial cross-sectional views of a helically wound lead of the type shown in <figref idref="f0004">FIG. 6</figref>. The lead comprises an outer lead body 80; a plurality of helically wound, co-radial lead filers 82; and a stylet lumen 84. As stated previously, a stylet is a stiff, formable insert placed in the lead during implant so as to enable the physician to steer the lead to an appropriate location. <figref idref="f0005">FIG. 10</figref> illustrates four separate, co-radially wound filers 86, 88, 90 and 92 which are electrically insulated from each other and electrically couple a single electrode 62 (<figref idref="f0004">FIG. 6</figref>) to a single contact 64 (<figref idref="f0004">FIG. 6</figref>).
As can be seen, the lead filers 82 have a specific pitch and form a helix of a specific diameter. The helix diameter is relevant in determining the inductance of the lead. These filers themselves also have a specific diameter and are made of a specific material. The filer diameter, material, pitch and helix diameter are relevant in determining the impedance of the lead. In the case of a helically wound lead, the inductance contributes to a frequency dependent impedance. <figref idref="f0005">FIGs. 12 and 13</figref> are longitudinal and radially cross-sectional views, respectively, of a cabled lead. The lead comprises outer lead body 94, stylet lumen 96, and a plurality (e.g. four-to-eight) of straight lead filers 98.
<figref idref="f0006">FIG. 14</figref> is an exploded view of a neurostimulation system that includes an extension 100 configured to be coupled between a neurostimulator 102 and lead 104. The proximal portion of extension 100 comprises a connector 106 configured to be received or plugged into connector block 109 of neurostimulator 102. The distal end of extension 100 likewise comprises a connector 110 including internal contacts 111 configured to receive the proximal end of lead 104 having contacts 112 thereon. The distal end of lead 104 includes distal electrodes 114.
<figref idref="f0006">FIG. 15</figref> is a cross-sectional view of extension 100. Lead extension 100 has a typical diameter of 2.54 mm (0.1 inch), which is significantly larger than that of lead 104 so as to make extension 100 more durable than lead 104. Extension 100 differs from lead 104 so as to make extension 100 more durable than lead 104. Extension 100 differs from lead 104 also in that each filer 106 in lead body 100 is helically wound or coiled in its own lumen 108 and not co-radially wound with the rest of the filers as was the case in lead 104.
The diameter of typical percutaneous leads is approximately 1.27 mm (0.05 inch). This diameter is based upon the diameter of the needle utilized in the surgical procedure to deploy the lead and upon other clinical anatomical requirements. The length of such percutaneous SCS leads is based upon other clinical anatomical requirements. The length of such percutaneous SCS leads is typically 28 centimeters; however, other lengths are utilized to meet particular needs of specific patients and to accommodate special implant locations.
Lead length is an important factor in determining the suitability of using the lead in an MRI environment. For example, the greater length of the lead, the larger the effect of loop area that is impacted by the electromagnetic field (i.e. the longer the lead, the larger the antenna). Furthermore, depending on the lead length, there can be standing wave effects that create areas of high current along the lead body. This can be problematic if the areas of high current are near the distal electrodes.
Compared to the helically wound lead, the cable lead has a smaller DC resistance because the length of the straight filer is less than that of a coiled filer and the impedance at frequency is reduced because the inductance has been significantly reduced. It has been determined that the newer cabled filer designs tend to be more problematic in an MRI environment than do the wound helix tiler designs. It should be noted that straight filers for cable leads sometimes comprise braided stranded wire that includes a number of smaller strands woven to make up each filer. This being the case, the number of strands could be varied to alter the impedance.
It has been discovered that high lead impedances at MRI operational frequencies can reduce the heating of an electrode during an MRI procedure. The high impedance acts as a choke for current flowing through the lead and, by restricting this current, electrode heating can be reduced. As previously alluded to, leads have been intentionally designed with low impedance to enhance system stimulation efficiency. The simplest way to increase the impedance of a lead is to increase its DC resistance. This may be accomplished in a number of ways that may, if desired, be combined to achieve an optimal impedance.
For example, the resistance R of a lead filer is governed by the equation: <maths id="math0001" num="Equation (1)"><math display="block"><mi>R</mi><mo>=</mo><mfrac><mi>L</mi><mi mathvariant="italic">σa</mi></mfrac></math><img file="EP1740258B2_D0001.tif" /></maths> where R is the resistance, L is the length of the filer, σ is the conductivity, and α is the cross-sectional area. Decreasing the conductivity and/or the cross-sectional area of the filer will increase resistance proportionally. One typical lead utilizes a stainless steel (non-cored MP35N) filer having a conductivity of 1.1x10<sup>6</sup> mhos/meter, a diameter of approximately 0.127 mm (0.005 inch), and a length of approximately 100 centimeters. Using Equation (1), the resistance R of the lead is approximately twenty ohms. If the diameter were reduced to 0.0508 mm (0.002 inch), R could be increased to approximately 710 ohms (or approximately 126 ohms for a 28 centimeter lead). This is still not sufficient for use in an MRI-safe neurological lead.
Impedance can also be obtained through inductance in accordance with the equation: <maths id="math0002" num="Equation (2)"><math display="block"><mi mathvariant="normal">Z</mi><mo>=</mo><mi mathvariant="normal">j</mi><mfenced separators=""><mn>2</mn><mi>πf</mi></mfenced><mi mathvariant="normal">L</mi></math><img file="EP1740258B2_D0002.tif" /></maths> where Z is the impedance, L is the inductance, and f is the frequency. Inductance L may be either distributed or discrete. For example, distributed inductance can be created by helically coiling the lead filers in such a way as to achieve the above described optimal impedance at MR frequencies. The inductance is governed by the equation: <maths id="math0003" num="Equation (3)"><math display="block"><mi>L</mi><mo>=</mo><mfrac><mrow><mi>μ</mi><msup><mi mathvariant="normal">N</mi><mn>2</mn></msup><mi>A</mi></mrow><mi>i</mi></mfrac></math><img file="EP1740258B2_D0003.tif" /></maths> where N is the number of turns in the helix, A is the cross-sectional area, I is the length, and µ is the permeability.
EXAMPLE 1
In the case of a 28 centimeter wound filer lead having a diameter of 1.27 mm (0.05 inch) and four turns per inch (i.e. approximately 44 turns for the entire lead), Equation (3) yields an inductance of approximately 1.1 µH. Substituting this value of inductance into Equation (2) yields an.absolute impedance of 442 ohms.
EXAMPLE 2
The DC resistance of a 0.127 mm (0.005 inch) diameter MP35N straight 28 centimeters filer is approximately 40 ohms. If it is assumed that only inductance can be varied to achieve an impedance in the range of 375 to 2000 ohms at 64 MHz, the inductance, as determined by Equation 2, should be approximately 1.0 µH to 5 µH. At 128 MHz, this range of inductance yields an impedance of approximately 804 to 4000 ohms. For a preferred impedance of 600 ohms, the inductance is approximately 1.5 µH.
EXAMPLE 3
Optimal impedance at MR frequencies is best obtained through a combination of impedance and inductance. Assume a helically coiled (approximately five turns per inch), 28 centimeter long braided stranded wire lead having a diameter of 0.0508 mm (0.002 inch). Equation 3 tells us that the inductance is approximately 1.72 µH. Substitution in Equation 2 yields an impedance of J691 ohms. The DC resistance of such a lead is approximately 126 ohms. Therefore, Z=126+j691 ohms. Thus, <maths id="math0004" num=""><math display="block"><mrow><mo>|</mo><mstyle mathvariant="bold-italic"><mi>Z</mi></mstyle><mo>|</mo></mrow><mo>=</mo><msup><mfenced separators=""><mn mathvariant="normal">12</mn><msup><mn>6</mn><mn>2</mn></msup><mo>+</mo><mn mathvariant="normal">69</mn><msup><mn>1</mn><mn>2</mn></msup></mfenced><mrow><mn>1</mn><mo>/</mo><mn>2</mn></mrow></msup><mspace width="1ex" /><mi mathvariant="bold">or</mi><mspace width="1ex" /><mn mathvariant="normal">703</mn><mspace width="1ex" /><mi mathvariant="italic">ohms</mi></math><img file="EP1740258B2_D0004.tif" /></maths>
One known helically wound lead has a DC resistance of approximately 3.3 ohms/centimeter. Thus, the DC resistance of 28 centimeter lead is approximately 92.4 ohms, and that of a 100 centimeter lead is approximately 330 ohms. The inductance of this known lead is approximately 31 nH/centimeter. Given this information and utilizing Equations (1) and (2), the impedance of known leads is approximately 9.0 ohms/centimeter at 43 MHz, 12.9 ohms/centimeter at 64 MHz, and 25.1 ohms/centimeter at 128 MHz. Thus, a 100 centimeter lead will have an absolute impedance of approximately 900 ohms at 43 MHz, 1290 ohms at 64 MHz, and 2510 ohms at 128 MHz.
In view of the above, the inventive lead should have a DC resistance of at least 375 ohms (preferably approximately 600 ohms) or alternatively at least 5 ohms/centimeter. By utilizing high resistance wires (in the order of 1x10<sup>4</sup> mhos/centimeter) and assuming a lead length of 100 centimeters, Equation (1) yields a DC resistance of approximately 2000 ohms.
It is recommended that the inductance at an MRI-safe lead should be greater than 31 µH /centimeter (e.g. 40 µH/centimeters). For example, assume a filer has a diameter of 0.127 mm (0.005 inch) and is configured to comprise 78.7 coils per centimeter. If the lead is 100 centimeters in length, the total number of coils is 7870. By utilizing the permeability of free space (i.e 1.26µH/meter) and substituting into Equation (3), the inductance is approximately 220 µH; i.e. 2.2 µH/centimeter for a 100 centimeter lead.
It is well known that the absolute value of impedance is given by: <maths id="math0005" num="Equation (4)"><math display="block"><mrow><mo>|</mo><mstyle mathvariant="bold-italic"><mi>Z</mi></mstyle><mo>|</mo></mrow><mo>=</mo><msup><mfenced separators=""><msup><mstyle mathvariant="bold-italic"><mi>R</mi></mstyle><mn>2</mn></msup><mo>+</mo><mi>ω</mi><msup><mstyle mathvariant="bold-italic"><mi>L</mi></mstyle><mn>2</mn></msup></mfenced><mrow><mn>1</mn><mo>/</mo><mn>2</mn></mrow></msup></math><img file="EP1740258B2_D0005.tif" /></maths> where R is the DC resistance, L is the inductance, and ω=2 n f where f is the frequency. With R=2000 ohms and L=220 mH, |Z|≅59.5 K-ohms at 43 MHz, and |Z|≅88.5 K-ohms at 64 MHz.
Using the above derived values, an MRI-safe lead might have a maximum DC resistance of 20 ohms/centimeter and a maximum inductance of 2.2 µH /centimeter. The absolute impedance may be as high as 595 ohms/centimeter at 43 Hz and 885 ohms/centimeter at 64 MHz.
A discrete inductor in the form of, for example, a hybrid component or wound helix in the conductor path of the lead may be utilized to provide inductance, and therefore impedance. In this way, a frequency-dependent impedance can be added at one of more locations in the lead. One such location may be within the lead's distal electrode, which will protect the connections to the inductor. One terminal of the inductor could be attached directly to the electrode, and the other terminal may be attached to the filer. It has been found that placing the inductor close to the distal electrode minimizes heating during an MR scan.
The discrete inductor comprises a coil of wire of, for example, cylindrical or torroidal construction. While both may be accommodated in a cylindrical package that may fit easily inside a lead electrode, it should be clear that packages of other shapes may be accommodated. For example, <figref idref="f0007">FIG. 16</figref> illustrates a cylindrically packaged discrete inductor 116 configured within distal electrode 114. <figref idref="f0007">FIG. 17</figref> is a cross-sectional view of a prismatically packaged discrete inductor 118 configured within distal electrode 114, and <figref idref="f0007">FIG. 18</figref> is a cross-sectional view of a quadripolar coaxially wound lead including outer lead body 120, stylet lumen 122, and at least four helically and coaxially wound lead filers 124. The lead shown in <figref idref="f0007">FIG. 18</figref> provides for a high helix angle and lead inductances that reach or exceed 40µH/cm. Each filer 124 can be individually insulated or positioned in its own sleeve. Furthermore, each filer 124 may be wound in either direction; and for added strength, certain ones of the filers may be wound in opposite directions.
There are a number of techniques that may be utilized to attach a discrete inductor to a lead electrode; e.g. welding, soldering, using a conductive epoxy, etc. Furthermore, while the discrete inductor is preferably placed inside the distal electrodes, it could also be placed inside the proximal electrodes and still have the benefit of the mechanical protection afforded by the electrode. The discrete inductor could also be placed within the lead body.
While at least one exemplary embodiment has been presented in the foregoing detailed description of the invention, it should be appreciated that a vast number of variations exist. For example, while the invention has been described in connection with neurostimulation systems, the invention is equally applicable to other lead assemblies (e.g. implantable cardiac leads) that may be adversely impacted in high frequency environments such as is encountered during an MRI scan. It should also be appreciated that the exemplary embodiment or exemplary embodiments are only examples, and are not intended to limit the scope, applicability, or configuration of the invention in any way. Rather, the foregoing detailed description will provide those skilled in the art with a convenient road map for implementing an exemplary embodiment of the invention, it being understood that various changes may be made in the function and arrangement of elements described in an exemplary embodiment without departing from the scope of the invention as set forth in the appended claims.
Contents8
12 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| WO03063953A2 | Cites | World Intellectual Property Organization (WIPO) | Opposition |
| US2002095084A1 | Cites | United States of America | Opposition |
| US2003009207A1 | Cites | United States of America | Opposition |
| US6032063A | Cites | United States of America | Opposition |
| US2002095084A1 | Cites | United States of America | – |
| US2003009207A1 | Cites | United States of America | – |
| US2003014080A1 | Cites | United States of America | – |
| US4947866A | Cites | United States of America | – |
| US5036862A | Cites | United States of America | – |
| US5335657A | Cites | United States of America | – |
| US6032063A | Cites | United States of America | – |
| US6741892B1 | Cites | United States of America | – |
| WO03063953A2 | Cites | World Intellectual Property Organization (WIPO) | – |
71 members in 5 offices
Priority claims11
| Document | Office | Kind | Date |
|---|---|---|---|
| 557991P | United States of America | – | |
| 55799104 | United States of America | P | |
| 945739 | United States of America | – | |
| 94573904 | United States of America | A | |
| 2004040082 | United States of America | W | |
| 557991P | – | – | – |
| 945739 | – | – | – |
| US2004040082 | – | – | – |
| US20040557991P | – | – | – |
| US20040945739 | – | – | – |
| WO2004US40082 | – | – | – |
Members71
| Document | Office | Kind | |
|---|---|---|---|
| US2005070972A1 | United States of America | A1 | |
| WO2005030322A1 | World Intellectual Property Organization (WIPO) | A1 | |
| US2005222642A1 | United States of America | A1 | |
| US2005222647A1 | United States of America | A1 | |
| US2005222656A1 | United States of America | A1 | |
| US2005222657A1 | United States of America | A1 | |
| US2005222658A1 | United States of America | A1 | |
| US2005222659A1 | United States of America | A1 | |
| WO2005102444A2 | World Intellectual Property Organization (WIPO) | A2 | |
| WO2005102445A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO2005102446A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO2005102447A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO2006093685A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO2006093686A2 | World Intellectual Property Organization (WIPO) | A2 | |
| WO2006093686A3 | World Intellectual Property Organization (WIPO) | A3 | |
| EP1740258A2 | European Patent Office (EPO) | A2 | |
| EP1740260A1 | European Patent Office (EPO) | A1 | |
| EP1742701A1 | European Patent Office (EPO) | A1 | |
| US7174219B2 | United States of America | B2 | |
| WO2005102444A3 | World Intellectual Property Organization (WIPO) | A3 | |
| EP1899000A2 | European Patent Office (EPO) | A2 | |
| EP1740260B1 | European Patent Office (EPO) | B1 | |
| EP1742701B1 | European Patent Office (EPO) | B1 | |
| ATE476219T1 | Austria | T1 | |
| ATE476220T1 | Austria | T1 | |
| DE602004028519D1 | Germany | D1 | |
| DE602005022690D1 | Germany | D1 | |
| EP1740258B1 | European Patent Office (EPO) | B1 | |
| ATE485860T1 | Austria | T1 | |
| US7844343B2 | United States of America | B2 | |
| US7844344B2 | United States of America | B2 | |
| DE602004029822D1 | Germany | D1 | |
| US7877150B2 | United States of America | B2 | |
| US2011071604A1 | United States of America | A1 | |
| US2011071605A1 | United States of America | A1 | |
| US2011112615A1 | United States of America | A1 | |
| US8364286B2 | United States of America | B2 | |
| EP2599520A1 | European Patent Office (EPO) | A1 | |
| EP2599521A1 | European Patent Office (EPO) | A1 | |
| EP2599522A1 | European Patent Office (EPO) | A1 | |
| US2013204337A1 | United States of America | A1 | |
| US8620453B2 | United States of America | B2 | |
| US8620454B2 | United States of America | B2 | |
| US8676340B2 | United States of America | B2 | |
| US2014107743A1 | United States of America | A1 | |
| US2014200643A1 | United States of America | A1 | |
| EP2599520B1 | European Patent Office (EPO) | B1 | |
| US2014336736A1 | United States of America | A1 | |
| US2014336737A1 | United States of America | A1 | |
| US2014336738A1 | United States of America | A1 | |
| US8989840B2 | United States of America | B2 | |
| US2015190640A1 | United States of America | A1 | |
| US9155877B2 | United States of America | B2 | |
| US9227055B2 | United States of America | B2 | |
| US9265939B2 | United States of America | B2 | |
| US9272144B2 | United States of America | B2 | |
| US9278211B2 | United States of America | B2 | |
| US9289604B2 | United States of America | B2 | |
| US9302101B2 | United States of America | B2 | |
| EP1899000B1 | European Patent Office (EPO) | B1 | |
| US2016175596A1 | United States of America | A1 | |
| US2016199640A1 | United States of America | A1 | |
| US9643009B2 | United States of America | B2 | |
| US9737704B2 | United States of America | B2 | |
| US2017239460A1 | United States of America | A1 | |
| US2017340878A1 | United States of America | A1 | |
| EP1740258B2This record | European Patent Office (EPO) | B2 | |
| EP2599522B1 | European Patent Office (EPO) | B1 | |
| EP2599521B1 | European Patent Office (EPO) | B1 | |
| US10391308B2 | United States of America | B2 | |
| US10463851B2 | United States of America | B2 |
76 legal events, as 7 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal feeWithdrawnR119 | R119 | DE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Patent maintained in amended form27A | 27A | EP | |
| Designated contracting statesAK | AK | EP | |
| Epo decision maintaining patent in amended form now finalR102 | R102 | DE | |
| Patent maintained in amended formORIGINAL CODE: 0009272PUAH | PUAH | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: PATENT MAINTAINED AS AMENDEDSTAA | STAA | EP | |
| Fee paymentPLFP | PLFP | FR | |
| Appeal procedure closedAppealORIGINAL CODE: EPIDOSNNOA9OAPBU | APBU | EP | |
| Fee paymentPLFP | PLFP | FR | |
| Fee paymentPLFP | PLFP | FR | |
| Fee paymentPLFP | PLFP | FR | |
| Date of receipt of statement of grounds of appeal recordedAppealORIGINAL CODE: EPIDOSNNOA3OAPBQ | APBQ | EP | |
| Appeal reference modifiedAppealORIGINAL CODE: EPIDOSCREFNOAPAH | APAH | EP | |
| Appeal reference recordedAppealORIGINAL CODE: EPIDOSNREFNOAPBM | APBM | EP | |
| Date of receipt of notice of appeal recordedAppealORIGINAL CODE: EPIDOSNNOA2OAPBP | APBP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Reply of patent proprietor to notice(s) of opposition receivedOppositionORIGINAL CODE: EPIDOSNOBS3PLBB | PLBB | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Information modified related to communication of a notice of opposition and request to file observations + time limitOppositionORIGINAL CODE: EPIDOSCOBS2PLAF | PLAF | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Opposition filed against patentOppositionR026 | R026 | DE | |
| Gb: european patent ceased through non-payment of renewal feeCeasedGBPC | GBPC | EP | |
| Opposition filedOpposition26 | 26 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Notice of opposition and request to file observation + time limit sentOppositionORIGINAL CODE: EPIDOSNOBS2PLAX | PLAX | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Opposition filedOppositionORIGINAL CODE: 0009260PLBI | PLBI | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Discontinued in the netherlands as no translation has been filedVDEP | VDEP | NL | |
| Corresponds to:REF | REF | EP | |
| European patents granted designating irelandGrantedFG4D | FG4D | IE | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| Designated contracting statesAK | AK | EP | |
| European patent grantedGrantedFG4D | FG4D | GB | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Information related to communication of intention to grant a patent modifiedORIGINAL CODE: EPIDOSCIGR1GRAC | GRAC | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| Request for extension of the european patent (deleted)DAX | DAX | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Availability of information related to the publication of the international search reportORIGINAL CODE: 0009015PUAK | PUAK | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Request for extension of the european patentAX | AX | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 1740258
- Publication, DOCDB
- 1740258
- Publication, EPODOC
- EP1740258
- Application
- 48125694
- Application, DOCDB
- 04812569
- Application, EPODOC
- EP20040812569
Titles3
- German
- MRT-SICHERES IMPLANTIERBARES MEDIZINPRODUKT
- English
- MRI-SAFE IMPLANTABLE MEDICAL DEVICE
- French
- DISPOSITIF MEDICAL IMPLANTABLE SANS IMAGERIE PAR RESONANCE MAGNETIQUE
Classification
- CPC, 5
- A61N1/0534
- A61N1/36071
- A61N1/086
- A61N1/0551
- A61N1/05
- IPC, 5
- A61N1 00
- A61N1 05
- A61N1 34
- A61N1 36
- A61N1 375
Designated states29
- Contracting states, 29
- Austria
- Belgium
- Bulgaria
- Switzerland
- Cyprus
- Czechia
- Germany
- Denmark
- Estonia
- Spain
- Finland
- France
- United Kingdom
- Greece
- Hungary
- Ireland
- Iceland
- Italy
- Liechtenstein
- Luxembourg
- Monaco
- Netherlands (Kingdom of the)
- Poland
- Portugal
and 5 moreShow fewer
- Romania
- Sweden
- Slovenia
- Slovakia
- Türkiye